Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Alopecia areata often recurs after treatment with diphenylcyclopropenone.

This study found that Diphenylcyclopropenone (DCP) was effective for treating extensive alopecia areata in Thai patients, although a high relapse rate suggests maintenance therapy might be necessary.

Among pediatric alopecia areata patients treated with DPCP, this study reported complete hair regrowth in 8.8% and any regrowth in 61.8% after one year, with better outcomes for those with milder initial symptoms and longer treatment durations.

This study found that topical diphenylcyclopropenone is an effective treatment for extensive alopecia areata, with significant hair regrowth reported in most patients, though effectiveness varied with disease characteristics.

This study found that dexamethasone treatment inhibited the inflammatory response and the induction of ornithine decarboxylase activity in mouse skin after TPA application, although the effect on ODC was weaker during the hyperplastic stage.

This study observed that while dexamethasone-cyclophosphamide pulse therapy is relatively free from hypertension and diabetes compared to conventional steroids in pemphigus patients, it frequently causes generalized weakness and flushing.

In this study, treatment with DPCP alone was more effective for hair regrowth and presented fewer side effects in chronic extensive alopecia areata compared to combination therapy with DPCP and anthralin.

This study found that nanostructured lipid carriers with more soybean phosphatidylcholine provided better skin retention and follicular targeting for diphencyprone compared to other formulations and controls.

This study demonstrated that intradermal treatment with a medical device using Polynucleotides High Purification Technology (PN HPT) significantly improved skin surface, firmness, pigmentation, and radiance in 30 Asian subjects, with benefits lasting up to six months and no adverse events reported.

Organizations help patients access discounts for expensive dermatology medications.

This study found that diphenylcyclopropenone therapy resulted in over 50% hair regrowth in 71% of alopecia totalis patients, with a significant relapse association with thyroid disease, suggesting treatment could be viable but should continue for at least two years.

This study found that diphenylcyclopropenone (DPCP) was more effective and better tolerated than dinitrochlorobenzene (DNCB) in promoting hair regrowth in patients with alopecia areata.

This study suggests that PDCD4 regulates keratinocyte proliferation and contact inhibition, playing a role in epidermal homeostasis and wound healing.

This study observed that PCE-DP may improve skin pigmentation by increasing epidermal turnover and inhibiting melanin uptake and inflammation in human epidermal keratinocytes.

This study found that adding PRP to DPCP treatment for severe alopecia areata did not enhance effectiveness compared to DPCP alone.

This study found that a single intradermal injection of human dermal papilla cells increased hair follicle number and thickness in pigs, suggesting potential effectiveness for hair growth in humans.

This study found that reduced plasma DIAPH1 levels were associated with polycystic ovary syndrome, suggesting DIAPH1 as a potential predictive factor for the condition.

This study found that higher concentrations of topical diphenylcyclopropenone, especially when prepared with acetone, showed better stability over 6 months compared to lower concentrations.

Educational efforts can reduce harmful chemical exposure from hair products in pregnant Women of Color.

This study examined immune responses to Diphencyprone and found that its induced skin reactions have higher levels of negative immune regulators compared to psoriasis, suggesting differences in immune regulation may contribute to psoriasis chronicity.

This study observed that 6.7% of patients treated with diphencyprone for alopecia areata developed vitiligo, with varying patterns and improvements noted among cases.

This study established a protocol to isolate and culture dermal papilla cells from human hair follicles, suggesting alkaline phosphatase activity as a key marker to differentiate them from human fibroblasts.

This study found that both new and old formulas of DCP for treating alopecia areata resulted in similar hair regrowth, but tolerance was significantly better with DCP in isopropanol.

This paper discusses various toxicological properties of diphenyl cresyl phosphate, highlighting its low acute toxicity, potential neurotoxicity linked to o-cresyl phosphate content, and the lack of data for inhalation exposure, but presents no new experimental findings.

New method quickly and accurately measures dexpanthenol in hair products.

This article reviews human placenta hydrolysates and their complex molecular mechanisms in treating various conditions but does not present new clinical findings.

In this study, cyproterone acetate at 2 mg daily was found to be as effective as higher doses in reducing hair growth for hirsute women over 12 months.

This study found that dracorhodin perchlorate improved wound healing in diabetic rats by regulating the TLR4 pathway and related inflammatory factors.

This study found that treatment with diphenylcyclopropenone led to more than 75% hair regrowth in 33.3% of patients with alopecia totalis or alopecia universalis, despite notable side effects.